6N7-23247-97072
2 vaccinations
1 coded response
15 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 190 / PA
- Registered
- 2021-04-13
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-13
Registered in v-safe
-
2021-04-13
Dose 1 — Pfizer-BioNTech
- 2021-04-13
- 2021-04-14
- 2021-04-15
- 2021-04-17
- 2021-04-18
- 2021-04-19
- 2021-04-30
-
2021-05-04
Dose 2 — Pfizer-BioNTech
- 2021-05-04
-
2021-05-05
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Headache, Muscle or body achesAdult check-in
- 2021-05-06
- 2021-05-07
- 2021-05-11
- 2021-05-27
- 2021-06-03
-
2021-08-05
Survey response — 3 months, dose 2MedDRA: Nasopharyngitis, Rhinorrhoea — Feeling: GoodFree text: Head cold, runny noseMedDRA releases: 2021-09,2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-13 | Pfizer-BioNTech | |
| 2 | 2021-05-04 | Pfizer-BioNTech |
Free text
Release 9 — 3 months, dose 2
Symptoms: Head cold, runny nose
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | ✓ | · | ✓ |
| SD | Rhinorrhoea | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release